Tweetable abstract One year later, the impact of the COVID-19 pandemic on business practices, supply chains, timelines and analytical needs for COVID-19 clinical trials have been felt across the bioanalytical community, as therapeutics may now require SARS-CoV-2 antigen and serological testing.
Keywords: COVID-19; NAAT; SARS-CoV-2 antigen; bioanalysis; clinical trials; serology.